Study reveals epigenetic changes also play a role in breast cancer risk

Breast cancer runs in families; however, genetic predisposition (such as being BRCA1 or BRCA2 mutation carriers) explains only a portion of this observation. Epigenetic changes (modifications in the genome that alter gene expression but do not affect the DNA sequence per se) have been shown to also play a role in breast cancer risk.

Researchers from the Columbia University Medical Center in New York have now examined whether a specific epigenetic modification (more specifically, methylation of the DNA) can be associated to breast cancer family history in unaffected women from high-risk breast cancer families. This important work suggests that the levels of DNA methylation in white blood cells from cancer-free women could be one of the factors playing a role in the clustering of breast cancer in families with extensive cancer histories within its members.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Two analgesic drugs may one day be repurposed as anti-tumor therapies